Navigation Links
NuVasive Licenses Its 'Insert and Rotate' Technology
Date:10/8/2007

SAN DIEGO, Oct. 8 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today the license of its "insert and rotate" method technology to Theken Spine, LLC.

Under the agreement, Theken Spine was granted a non-exclusive license to use NuVasive's patented "insert and rotate" method of US Patent No. 6,290,724 in exchange for royalty payments to be made to NuVasive. The patented "insert and rotate" method is a means of inserting a device between adjacent vertebrae and then rotating the device for the purpose of separating and stabilizing those vertebrae.

Commenting on the patent license agreement, Alexis V. Lukianov, Chairman and Chief Executive Officer, said, "We view this license arrangement as a solid validation of our unique and growing Intellectual Property platform. We commend Theken Spine for their cooperation in working to conclude this agreement."

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $3.6 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS, as well as a growing offering of cervical and motion preservation products.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. US Government Licenses New Hypertension Drug
2. Panacea Biotec In-Licenses FMD Vaccine
3. Thailand Goes Ahead With Licenses for Generic Drugs
4. Swedish Biotech Licenses HIV Drug to China for Development
5. More Foreign Trained Doctors Receive Licenses
6. FDA Licenses First US Vaccine Against Avian Flu
7. Thailand Will Not Issue Compulsory Licenses for Patented Drugs
8. Spacer Insertion May Offer Less Invasive Option for Lumbar Problems
9. RotaTeq Gets US Approval
10. Vedic vibration technology- the new cure for arthritis
11. Biotechnology industry expected to grow into a three billion dollar industry by 2002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...t quick to condemn hurtful comments, study suggest... -- Many people overestimate how strongly they wou.... , Sixty-three percent of study participants ...tner for an experiment with a white person rather ... racist comments about the black person when he le...
(Date:1/8/2009)...ds of local dance students will dance to raise mon...EAPOLIS, Jan. 8 , , , WHO: ...will show off their talent in the 3rd annual Dance... by Dance Arts Centre. The, event...chor., Participants raise money ...
(Date:1/8/2009)...Announced Acquisition in 2009 Continues Growth Tre...ire-FirstCall/ -- IPC The Hospitalist Company, Inc...t physician group practice company, announced toda... Midwest Acute Care Consultants, Inc. (MACC) in St...inued expansion in the St. Louis market, where IPC...
(Date:1/8/2009)...GTON, Jan. 8 The Pew Ch... has been named director, chemical and food safety...cy program. Olson, who was formerly deputy staff d...e on Environment and Public Works, brings nearly 2...consumer advocacy to Pew. , , "We are excited ...
Breaking Medicine News(10 mins):Health News:Many Turn Blind Eye to Racism 2Health News:Dance With Courage to Benefit Camp Courage 2Health News:IPC The Hospitalist Company Acquires Missouri Practice Group 2Health News:Veteran Environmental Health Expert Erik D. Olson to Join Pew 2
...ahya Jammeh, the president of Gambia, a very small...cure for AIDS.// He has no medical degree and ...m by his ancestors. But the country’s own health ...ied that the president could be bringing false hop...
...David Cameron is putting his best foot forward wit...as preparations are rife for the parties’ annual s... always reiterated that curtailing health problems...e problems and the risk of sexually transmitted di...
...ine in the death rate due to homicide, HIV disease...ly among women are some of the key reasons// behin... blacks and whites in the United States, although ... study is published in the March 21 issue of JAMA....
...la Saturday urged expatriates from the state to do...d primary health centers. "We require a lot of h...e large number of Keralites settled abroad towards...pitals, especially those at the village and block ...
Other Medicine News:Health News:Black-white Life Expectancy Gap Reduces, Yet Remains Significant 2
(Date:1/8/2009)...EUVEN, Belgium, January 9 /PRNewswire-FirstCall/ -...died in the Treatment of,Vitreomacular Adhesion i...onext Brussels: THR), a biotechnology company,foc...cular disease and,cancer, announces today that it...croplasmin for the non-surgical treatment of back ...
(Date:1/8/2009)...HICAGO, Jan. 8 If you are taking p... you,re not alone. Half of the people taking,pres... reasons are,varied -- they forget, are busy with...ot to. Noncompliance has been called the Achilles ...ral Everett Koop commented, "Drugs don,t,work in ...
(Date:1/7/2009)...NDIANAPOLIS, Jan. 7 Eli ...that it received a complete response letter from,...anzapine long-acting,injection (LAI) for acute an...s. Lilly is continuing to work with the agency on ...does not require any additional clinical trials fo...
(Date:1/7/2009)...RICK, Md., Jan. 7 ImQuest Life Sci... an IND application to the Food and Drug Administr...lead pyrimidinedione HIV inhibitor IQP-0410. ImQue... the first quarter of 2009. IQP-0410 is a novel sm... as a nonnucleoside reverse transcriptase inhibito...
Breaking Medicine Technology:ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease 2ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease 3ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease 4Good Medicine: Smarter Smartphones for People With Chronic Disease 2FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 2FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 3FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 4FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 5FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 6ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Delaware Man Spearheads Brain Tumor Awareness 7970 1Delaware Man Spearheads Brain Tumor Awareness 7970 2Medical Device Producers Express Interest in Purolator USA 26apos 3Bs Express Service and Customer Service 26868 1Medical Device Producers Express Interest in Purolator USA 26apos 3Bs Express Service and Customer Service 26868 2New Trend of Healthcare Companies Sending Patients Abroad for Surgery is Dangerous Says James Goldberg Whose Son Died Following Surgery in Thailand 26863 1New Trend of Healthcare Companies Sending Patients Abroad for Surgery is Dangerous Says James Goldberg Whose Son Died Following Surgery in Thailand 26863 2Never Events Responsible for One Out of Six Med Mal Liability Claims Says Aon 26859 1Never Events Responsible for One Out of Six Med Mal Liability Claims Says Aon 26859 2Never Events Responsible for One Out of Six Med Mal Liability Claims Says Aon 26859 3Never Events Responsible for One Out of Six Med Mal Liability Claims Says Aon 26859 4Never Events Responsible for One Out of Six Med Mal Liability Claims Says Aon 26859 5
...jection of peramivir for eight,days protected mice...hibited virus replication, supporting the use of t...EMPHIS, Tenn., May 01, 2007 /PRNewswire-USNewswire...ns significant protection,during a pandemic of the...of mouse studies conducted by investigators at St....
...ESS WIRE)--May 1, 2007 - Teva,Pharmaceutical Indus...hat data from a 36-week, randomized, double-blind,...hat an oral 0.6 mg,dose of laquinimod given daily ...MRI) disease activity by 38 percent in RRMS,patien...a favorable,trend towards reducing annual relapse ...
Other Medicine Technology:Peramivir Protects Mice From Lethal H5N1 Infection 2Peramivir Protects Mice From Lethal H5N1 Infection 3Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 2Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 3Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 4Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 5Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 6
Eliminating the need for any manual pipetting, the HydraPLUS delivers precise micro-volumes of sample directly from primary tubes to four HYDRASYS sample applicators contained in a built-in humidity
...ECHET EXTENDER® is a new device for skin exten... elastomer strips, it allows a constant and powerf...r devices capacities. Such effectiveness makes the...it is removed before 30 days. Furthermore it is in...
Inquire
Inquire
Medicine Products: